High expression of long non‐coding RNA AFAP1‐AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

Abstract

To evaluate the clinical significance of lncRNAs in the resistance to cisplatin‐based chemoradiotherapy in esophageal squamous cell carcinoma (ESCC). We focused on lncRNAs which were frequently reported in ESCC or were involved in chemoradiotherapy resistance. LncRNA expressions were examined in paired cisplatin‐resistant and parental ESCC cell lines. Dysregulated lncRNAs were further measured in 162 pretreatment biopsy specimens of ESCC who received definitive chemoradiotherapy (dCRT). Then the correlations between lncRNA expression and response to dCRT and prognosis were analyzed. Three lncRNAs (AFAP1‐AS1, UCA1, HOTAIR) were found to be deregulated in cisplatin‐resistant cells compared with their parent cells. AFAP1‐AS1 was significantly up‐regulated in tumor tissues compared with adjacent normal tissues (P = 0.006). Furthermore, overexpression of AFAP1‐AS1 was closely associated with lymph node metastasis (P < 0.001), distant metastasis (P = 0.016), advanced clinical stage (P = 0.002), and response to dCRT (P < 0.001). Kaplan–Meier survival analysis revealed that high expression of AFAP1‐AS1 was significantly associated with shorter progression free survival (PFS) (median, 15 months vs. 27 months, P < 0.001) and overall survival (OS) (median, 29 months vs. 42 months, P < 0.001). In the multivariate analysis, high expression of AFAP1‐AS1 was found to be an independent risk factor to predict poor PFS (HR, 1.626; P = 0.027) and OS (HR, 1.888; P = 0.004). Thus, high expression of AFAP1‐AS1 could serve as a potential biomarker to predict tumor response and survival. Determination of this lncRNA expression might be useful for selection ESCC patients for dCRT. © 2016 The Authors. Molecular Carcinogenesis published by Wiley Periodicals, Inc.

AFAP1‐AS1: A novel oncogenic long non‐coding RNA in human cancers

“…30,35,[40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58] In this review, the related clinicopathological characteristics and molecular functions of this lncRNA in cancers are presented in Tables 1 and 2.…”

Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA‐101 in glioblastoma

“…Long noncoding RNAs (lncRNAs), generally longer than 200 nucleotides in length, are emerging as important regulators in tumor initiation and progression, as indicated by numerous studies in recent years . The key roles of lncRNAs played in drug resistance are also extensively reported . For instance, Zhang et al.…”

Long non-coding RNAs: New biomarkers for prognosis and diagnosis of colon cancer

“…37,38 Particularly in CRC, a research conducted by Wang et al manifested that AFAP1-AS1 was abnormally overexpressed in CRC tissues and positively associated with tumor-node-metastasis (TNM) stage, tumor size, and distant metastasis. In addition, in patients with overexpressed AFAP1-AS1, poorer OS and disease-free survival are more likely to occur.…”